Antiva Biosciences
Elaine Chien, MD, currently serves as Chief Medical Officer at Antiva Biosciences, Inc. since September 2023. Prior to this role, Elaine Chien was an independent consultant from 2010, providing strategic guidance to various biotechnology, medical device, and healthcare IT companies, particularly in women's and reproductive health. Notable previous positions include Vice President of Clinical Development and Medical Safety at Mirum Pharmaceuticals, where Elaine Chien assumed additional responsibilities during leadership transitions and led the global clinical development for volixibat. Other significant roles include Medical Advisor at Wildflower Health, where Elaine Chien contributed to the development of a health engagement app, and various consultancy positions at organizations such as Myovant Sciences and Clovis Oncology, focusing on clinical development and pharmacovigilance. Elaine Chien holds an MD from Northwestern University - The Feinberg School of Medicine and a BA in Economics from Northwestern University.
Antiva Biosciences
Antiva Biosciences, Inc. is a clinical stage biopharmaceutical company developing novel, topical therapeutics for the treatment of diseases caused by HPV infection. They aim to stop cancer before it starts by treating the pre-cancerous lesions caused by HPV.